E.coli xen14 strain荧光大肠杆菌菌株菌种 BioVector NTCC质粒载体菌种细胞基因保藏中心

E.coli xen14 strain荧光大肠杆菌菌株菌种 BioVector NTCC质粒载体菌种细胞基因保藏中心
E. coli - Xen14 bioluminescent pathogenic bacteria for in vivo and in vitro drug discovery. This product was derived from the parental strain E. coli WS2572, a clinical isolate from Weihenstephan Culture Collection. E. coli-Xen14 possesses a stable copy of the Photorhabdus luminescens lux operon on the bacterial chromosome.
Infectious disease is a perennially important area for both life science research and drug discovery. Some of the first applications of IVIS® imaging technology were in tracking infections and monitoring host responses, and these applications are still at the forefront of research. PerkinElmer's bioluminescent infectious disease light-producing microorganisms have been developed to mimic both acute and chronic standard infection protocols presently used by researchers, e.g., lung, sepsis, meningitis, GI, and biofilm infections.

Advantages of using bioluminescent light-producing microorganisms for drug discovery in vitro:

Rapid and readily amenable to high throughput screening, e.g., 96 or 384-well format
Sensitivity - subtle changes in cellular viability are rapidly detected
Inexpensive - no additional substrates needed for bacterial assays
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vivo:

Rapid identification of lead drug candidates
Real-time efficacy data
May help to decrease drug failure by allowing disease relapse to be monitored in the same animal
【Supplier来源】BioVector NTCC Inc.
TEL：+86-010-53513060
【Website网址】 http://www.biovector.net